Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer's disease

Novo Holdings United Kingdom United States of America Denmark

Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer's diseaseAlzheimer's disease is an area of very high unmet medical need with a lack of oral disease modifying therapiesNaveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings will join Asceneuron Board of DirectorsView original content:https://www.prnewswire.co.uk/news-releases/novo-holdings-leads-100-million-series-c-financing-of-asceneuron-to-advance-groundbreaking-therapy-for-alzheimers-disease-302197021.html